Rheumatology Journals

Rheumatology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Chung Y et al. - Allopurinol is a moderately active hypouricemic drug, that acts by inhibiting the xanthine oxidoreductase by oxypurinol, the active metabolite of allopurinol. Optimal use of allopurinol involves individualization of dose to attain a sufficient decrease in plasma urate concentrations. The initial use of an anti-inflammatory drug or low-dose colchicine decreases but does not eliminate the development of acute attacks of gout during the initiation of therapy with allopurinol. Monitoring of oxypurinol concentrations has shed some light on the efficacy of allopurinol but more data are required particularly in patients with renal impairment.

Today in Clinical Pharmacology...keeping you current

Taking the stress out of managing gout
Canadian Family Physician, 12/16/09

Rituximab and concomitant leflunomide for the treatment of rheumatoid arthritis
Rheumatology International, 12/16/09

First-line DMARD choice in early rheumatoid arthritis - Do prognostic factors play a role?
Rheumatology, 12/15/09

Today in Gout and Hyperuricemia...keeping you current

Taking the stress out of managing gout
Canadian Family Physician, 12/16/09

Clinical study of gout in North Kerala
Indian Journal of Rheumatology , 12/15/09

Treatment of chronic tophaceous gout with a free flap
Clinical Rheumatology, 12/14/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address